OBJECTIVES:  Tyrosine kinase inhibitor therapy (TKI) is a type of targeted therapy that inhibit signals needed for cancer cells to grow and divide. In this study, we assessed the trends in average wholesale prices (AWP) at the market entry for thyroid cancer – targeted therapy approved by the US Food and Drug Administration (FDA). METHODS:  AWP per unit at market entry data were derived from the RedBook. The AWP history was collected from the year of approval to April 2017. The daily defined dosage (DDD) for adult patients was obtained from FDA approved labels. AWP per DDD were computed. AWPs were adjusted for inflation by using the consumer price index (CPI). Descriptive statistics were performed in this study. RESULTS:  The FDA approved 4 tyrosine kinase inhibitor drugs for the indication of thyroid cancer in the period 2005-2016. The first TKI for thyroid cancer was approved in 2005 and deactivated in January 2008 with AWP of $174.90 per DDD, and then returned to the market in July 2008 with the same strength and package but with an AWP of $594.72 which represents a 246% increase than in the previous price.The median time between approval date and market entry was 38 days (106- 4 days.) The median AWP per DDD at market entry was $761.79 ($1396.87- $ 160.39.) The FDA-approved TKIs typically increased their AWP prices twice a year with average annual percent change 10%. The AWP per DDD at the market entry of the last approved TKI in 2015 was 552% higher than the AWP per DDD at the market entry of the first approved TKI in 2005. The AWPs per DDD at market entry were $160.39, $477.09, $1396.87 and $1,064.48 respectively during the time of the study. CONCLUSIONS: The market entry prices of TKIs for thyroid cancer substantially increased over the period of study.